Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

AAV-mediated gene therapy for focal epilepsy by expressing neuropeptide Y and Y2 receptor in rodent and non-human primate hippocampus

Terzic, Barbara ; Melin, Esbjörn LU orcid ; Fagergren, Pernilla ; Dobry, David ; Cattaneo, Stefano ; Giupponi, Iris ; Bettegazzi, Barbara ; Simonato, Michele ; Agerman, Karin and Kokaia, Merab LU , et al. (2025) In Molecular Therapy 33(9). p.4239-4258
Abstract

Epilepsy affects approximately 50 million people worldwide, and over 30% of patients are considered treatment resistant to currently available anti-seizure drugs. Neuropeptide Y (NPY) has been shown to inhibit excitatory synaptic transmission in hippocampal slices from human epilepsy patients via Y2 receptors (Y2Rs), and overexpression of NPY and/or Y2R in the hippocampus reduces seizures in rodent models of epilepsy. In this study, we demonstrate that AAV-mediated delivery of NPY and Y2R using a novel vector (SPK100.NPY-Y2R) inhibits seizures in rodents. SPK100.NPY-Y2R reduced spontaneous neuronal activity in primary rat cortical cultures and attenuated evoked neuronal activity in ex vivo slices of mouse hippocampus. Furthermore,... (More)

Epilepsy affects approximately 50 million people worldwide, and over 30% of patients are considered treatment resistant to currently available anti-seizure drugs. Neuropeptide Y (NPY) has been shown to inhibit excitatory synaptic transmission in hippocampal slices from human epilepsy patients via Y2 receptors (Y2Rs), and overexpression of NPY and/or Y2R in the hippocampus reduces seizures in rodent models of epilepsy. In this study, we demonstrate that AAV-mediated delivery of NPY and Y2R using a novel vector (SPK100.NPY-Y2R) inhibits seizures in rodents. SPK100.NPY-Y2R reduced spontaneous neuronal activity in primary rat cortical cultures and attenuated evoked neuronal activity in ex vivo slices of mouse hippocampus. Furthermore, intrahippocampal administration of SPK100.NPY-Y2R reduced the progression and duration of seizures in a rat model of rapid kindling. Parallel experiments confirmed that hippocampal overexpression of NPY and Y2R is also sufficient to reduce spontaneous seizures in a genetic mouse model of epilepsy (synapsin triple knockout). We also demonstrated successful magnetic resonance-guided convection enhanced delivery of SPK100.NPY-Y2R to the hippocampus of Papio hamadryas (baboon). This approach achieved favorable vector biodistribution and transduction in the hippocampus, with no observed adverse events. These findings support the development of an intrahippocampal AAV.NPY-Y2R therapy for treating seizures in patients with temporal lobe epilepsy.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
adeno-associated virus, baboon, calcium imaging, epilepsy, gene therapy, microelectrode array, neuropeptide Y, NPY, seizures, Y2 receptor
in
Molecular Therapy
volume
33
issue
9
pages
20 pages
publisher
Nature Publishing Group
external identifiers
  • scopus:105009483949
  • pmid:40517292
ISSN
1525-0016
DOI
10.1016/j.ymthe.2025.06.019
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2025 The Authors
id
0e549a2d-eb05-4274-9ecd-b459fd720297
date added to LUP
2026-01-21 15:48:58
date last changed
2026-01-22 14:09:40
@article{0e549a2d-eb05-4274-9ecd-b459fd720297,
  abstract     = {{<p>Epilepsy affects approximately 50 million people worldwide, and over 30% of patients are considered treatment resistant to currently available anti-seizure drugs. Neuropeptide Y (NPY) has been shown to inhibit excitatory synaptic transmission in hippocampal slices from human epilepsy patients via Y2 receptors (Y2Rs), and overexpression of NPY and/or Y2R in the hippocampus reduces seizures in rodent models of epilepsy. In this study, we demonstrate that AAV-mediated delivery of NPY and Y2R using a novel vector (SPK100.NPY-Y2R) inhibits seizures in rodents. SPK100.NPY-Y2R reduced spontaneous neuronal activity in primary rat cortical cultures and attenuated evoked neuronal activity in ex vivo slices of mouse hippocampus. Furthermore, intrahippocampal administration of SPK100.NPY-Y2R reduced the progression and duration of seizures in a rat model of rapid kindling. Parallel experiments confirmed that hippocampal overexpression of NPY and Y2R is also sufficient to reduce spontaneous seizures in a genetic mouse model of epilepsy (synapsin triple knockout). We also demonstrated successful magnetic resonance-guided convection enhanced delivery of SPK100.NPY-Y2R to the hippocampus of Papio hamadryas (baboon). This approach achieved favorable vector biodistribution and transduction in the hippocampus, with no observed adverse events. These findings support the development of an intrahippocampal AAV.NPY-Y2R therapy for treating seizures in patients with temporal lobe epilepsy.</p>}},
  author       = {{Terzic, Barbara and Melin, Esbjörn and Fagergren, Pernilla and Dobry, David and Cattaneo, Stefano and Giupponi, Iris and Bettegazzi, Barbara and Simonato, Michele and Agerman, Karin and Kokaia, Merab and Moon, Lawrence and Ramsburg, Elizabeth}},
  issn         = {{1525-0016}},
  keywords     = {{adeno-associated virus; baboon; calcium imaging; epilepsy; gene therapy; microelectrode array; neuropeptide Y; NPY; seizures; Y2 receptor}},
  language     = {{eng}},
  month        = {{09}},
  number       = {{9}},
  pages        = {{4239--4258}},
  publisher    = {{Nature Publishing Group}},
  series       = {{Molecular Therapy}},
  title        = {{AAV-mediated gene therapy for focal epilepsy by expressing neuropeptide Y and Y2 receptor in rodent and non-human primate hippocampus}},
  url          = {{http://dx.doi.org/10.1016/j.ymthe.2025.06.019}},
  doi          = {{10.1016/j.ymthe.2025.06.019}},
  volume       = {{33}},
  year         = {{2025}},
}